Investment
Features
FeesSafety
Academy
More
Pluang+

Compare UBC Medical Indonesia Tbk. (LABS) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance

UBC Medical Indonesia Tbk.Trade
Tempo Scan Pacific Tbk.Trade

Price performance (Past 24H)

Key statistics

UBC Medical Indonesia Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,590 (market cap 11.36T, 1.77M 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 19.7× UBC Medical Indonesia Tbk.'s market cap, and UBC Medical Indonesia Tbk. is more actively traded (3.48M versus 1.77M). Which is the better fit depends on your goals.

LABSTSPC
Market Cap
576.7B11.36T
Volume
3.48M1.77M
Lot
34.82K17.71K
Turnover
522.79M4.61B
Average Price
150.132,603.9
Value
522.79M4.61B
Indicative Equilibrium Price
1482,590
Indicative Equilibrium Volume
350300

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LABS
View details
TSPC
View details

About UBC Medical Indonesia Tbk.

PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.

Read more on LABS

About Tempo Scan Pacific Tbk.

PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.

Read more on TSPC